STIMULATION OF GLUCOSE UTILIZATION IN 3T3 ADIPOCYTES AND RAT DIAPHRAGM IN VITRO BY THE SULPHONYLUREAS, GLIMEPIRIDE AND GLIBENCLAMIDE, IS CORRELATED WITH MODULATIONS OF THE cAMP REGULATORY CASCADE

GÜNTER MÜLLER,* SUSANNE WIED, EVA-MARLEN WETEKAM, ANNA CRECELIUS, ANGELIKA UNKELBACH and JÜRGEN PFÜNDER

Hoechst Aktiengesellschaft Frankfurt a.M., SBU Metabolic Diseases H825, D-65926 Frankfurt am Main, Germany

(Received 20 September 1993; accepted 26 April 1994)

Abstract—The long-term hypoglycemic activity of sulphonylurea drugs has been attributed, in part at least, to the stimulation of glucose utilization in extra-pancreatic tissues. The novel sulphonylurea, glimepiride, gives rise to a longer lasting reduction in the blood sugar level in dogs and rabbits compared to glibenclamide (Geisen K, Drug Res 38: 1120-1130, 1988). This cannot be explained adequately by elevated plasma insulin levels. This study investigated whether this prolonged hypoglycemic phase was based on the drug's abilities to stimulate glucose utilization and affect the underlying regulatory mechanisms in insulin-sensitive cells in vitro. It was found that in the absence of added insulin, glimepiride and glibenclamide (1-50 nM) stimulated lipogenesis (3T3 adipocytes) and glycogenesis (isolated rat diaphragm) -4.5- and 2.5-fold, respectively, and reduced the isoproterenol-stimulated lipolysis (rat adipocytes) up to 40-60%. The increased glucose utilization was correlated with a 3-4-fold higher 2-deoxyglucose transport rate and amount of GLUT4 at the plasma membrane, as well as with increased activities of key metabolic enzymes (glycerol-3-phosphate acyltransferase, glycogen synthase) within the same concentration range. Furthermore, the low Kₐₐ cAMP-specific phosphodiesterase was activated 1.8-fold, whereas the cytosolic cAMP level and protein kinase A activity ratios were significantly lowered after incubation of isoproterenol-stimulated rat adipocytes with the sulphonylureas. In many of the aspects studied the novel sulphonylurea, glimepiride, exhibited slightly lower ED₅₀-values than glibenclamide. This study demonstrates correlations existing between drug-induced stimulation of glucose transport/metabolism and cAMP degradation/protein kinase A inhibition as well as between the relative efficiencies of glimepiride and glibenclamide in inducing these extra-pancreatic processes. Therefore, it is suggested that the stimulation of glucose utilization by sulphonylureas is mediated by a decrease of cAMP-dependent phosphorylation of GLUT4 and glucose metabolizing enzymes. The therapeutic relevance of extra-pancreatic effects of sulphonylureas, in general, and of the differences between glimepiride and glibenclamide as observed in vitro in this work, in particular, remain to be elucidated.

Key words: non-insulin-dependent diabetes mellitus; sulfonylureas; insulin signaling; glucose and lipid metabolism; protein kinase A

Sulphonylureas are widely used oral drugs for the treatment of NIDDM. Their initial hypoglycemic efficacy is generally explained by acute stimulation of the rate of insulin release from the pancreas. However, after long-term treatment of NIDDM patients with sulphonylurea compounds plasma insulin levels often return to pre-treatment levels without concomitant loss of hypoglycemic control or improved glucose tolerance [1, 2]. This has been attributed to increased glucose disposal by peripheral tissues, as observed during euglycemic clamp studies in rats, dogs [3, 4] and NIDDM patients [5, 6]. Direct stimulation of basal and/or insulin-dependent glucose transport and metabolism in muscle and fat cells [7, 8] or, alternatively, an improvement in the overall metabolic situation in muscle and fat tissues due to increased insulin and reduced glucose levels, would explain increased glucose utilization after sulphonylurea administration. Experimental conditions with tightly controlled insulin and glucose concentrations will help to discriminate between these possibilities.

Therefore, cellular and cell-free assays were used to determine insulin action derived from isolated rat and cultured 3T3 adipocytes, as well as isolated rat diaphragms. The effects of the sulphonylureas, glimepiride and glibenclamide, on the rate of
basal and insulin-stimulated glucose transport and metabolizing pathways and, in addition, on key regulatory processes of glucose metabolism, were investigated. The study was designed to allow comparison between glimepiride and glibenclamide, since it has been shown that glimepiride provokes a significantly prolonged blood sugar lowering phase compared to glibenclamide after oral or i.v. application in dogs and rabbits [9]. These observations suggested that glimepiride would exhibit stronger direct effects on the two major insulin-sensitive peripheral tissues, fat and muscle. The in vitro data from this study suggest that the molecular basis for the observed multiple stimulatory effects of glimepiride and glibenclamide on glucose transport and metabolism rely on the interference with the cAMP signalling cascade which may, thus, represent the primary target for sulphonylurea actions in peripheral tissues.

**MATERIALS AND METHODS**

**Materials.** Radiochemicals were bought from Amersham-Buchler (Braunschweig, Germany); 3T3 fibroblast clone A31 was obtained from the American Type Culture Collection (CCL 163). Male Wistar rats were bred and delivered by the Hoechst Aktiengesellschaft (Tierzucht Kastengrund, Germany); semi-synthetic human insulin (I 81 0182), glimepiride (HOE 490) and glibenclamide (Hb 419) were prepared by the Pharma Synthesis Department of Hoechst Aktiengesellschaft (Frankfurt, Germany); stock solutions of glimepiride and glibenclamide were prepared on the day of use as described previously [10]. 12-{[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino] dodecanoic acid was provided by Molecular Probes Inc. (Eugene, OR, U.S.A.) and dissolved in Krebs-Ringer-phosphate buffer containing 1.5% BSA and a 0.5 mM stock solution, which was made daily. All the other materials and chemicals were obtained as described previously [11, 12].

**Cell culture and incubation of 3T3 adipocytes.** This was done according to published methods [11] with modifications: cells were grown (150 or 35 mm culture plates per condition) in DMEM (25 or 2 mL per condition) containing 25 mM glucose, 10% FCS and antibiotics. Confluent and differentiated cells (80-90% of the cells expressed the adipocyte phenotype) were washed twice with Krebs-Ringer-phosphate buffer and then incubated in the same buffer (10 or 1 mL) with sulphonylurea or insulin as indicated.

**Metabolic labelling of 3T3 adipocytes.** Plates (150 mm) were washed twice with methionine-free DMEM (HEPES-based) containing 10% FCS, 5.5 mM glucose, 50 units/mL penicillin, 50 μg/mL streptomycin sulphate and then incubated (20 hr, 37°) with 10 mL of the same medium supplemented with 0.1 mM L-[35S]methionine (0.1 μCi) in the absence or presence of sulphonylurea and insulin under constant bubbling with 5% CO2/95% O2. The plates were then washed twice with ice-cold DMEM containing 10 mM unlabelled methionine.

**Preparation of 3T3 adipocyte homogenate and membrane fractions.** Prior to homogenization, 150 mm plates were washed with DMEM as above and then once with 10 mL of PBS containing 1 mM EDTA, 0.25 M sucrose. Monolayers from four plates were scraped into 24 mL of ice-cold Tris-HCl/EDTA/sucrose buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.25 M sucrose) and immediately homogenized with 10 strokes of a motor-driven Teflon-in-glass homogenizer. PMSF (final concentration 0.2 mM) was added to the cell suspension prior to homogenization.

The homogenate was centrifuged (16,000 g, 20 min). The pellet was resuspended in 6 mL of 10 mM Tris-HCl (pH 7.4), 1 mM EDTA and applied on to a sucrose cushion (1.12 M sucrose in Tris-HCl/EDTA). After centrifugation (100,000 g, 1 hr), the plasma membranes were removed from the top of the sucrose cushion, suspended in 25 mL of Tris-HCl/EDTA, 0.1 mM PMSF, recovered by centrifugation (30,000 g, 30 min) and resuspended in 0.5 mL of Tris-HCl/EDTA, 0.1 mM PMSF. The initial 16,000 g supernatant was centrifuged (48,000 g, 30 min). LDM were recovered from the supernatant by centrifugation (200,000 g, 2 hr). The pellet was suspended in 0.5 mL of Tris-HCl/EDTA, 0.1 mM PMSF. The membrane fractions were assayed for the activity of the plasma membrane marker enzyme, 5'-nucleotidase [13], which was enriched 7.5-fold (plasma membranes) and 0.4-fold (LDM) towards the homogenate.

**Isolation and incubation of rat adipocytes, preparation of homogenate and subcellular fractions (LDM, cytosol).** These were performed according to published procedures [12, 14].

**Preparation and incubation of rat diaphragm and preparation of homogenate.** Intact hemidiaphragms were dissected from male Wistar rats as described [15] and incubated in DMEM (10 mL/hemidiaphragm) with constant bubbling of O2:CO2 (95:5). For treatment with sulphonylureas or insulin, the hemidiaphragms were incubated (37°) in Krebs-Henseleit buffer plus 5 mM glucose for the periods indicated. For assaying glycogenesis, the hemidiaphragms were blotted on tissue, washed twice in the same buffer without glucose and then incubated with the same buffer (3 mL/hemidiaphragm) containing 5 mM [U-14C]glucose (1 μCi/mL). The incubation was terminated after 20 min by transferring the diaphragms into fresh buffer containing 5 mM glucose. For preparation of the homogenate, the diaphragms were blotted and frozen in liquid nitrogen. The frozen diaphragms (pool of four) were ground manually in a porcelain mortar and then homogenized at 0° in 2 mL of 25 mM Tris-HCl (pH 7.4), 100 mM NaF, 5 mM EDTA, 0.1 mM PMSF, the homogenate was then centrifuged (10,000 g, 20 min). The supernatant was used for the determination of radiolabelled glycogen for the glycogenesis or glycogen synthase assays (see below).

**Glycogenesis.** Samples of the supernatant from the diaphragm homogenate were heated (45 min, 100°) in 30% KOH (1 mL/50 mg tissue) and then adjusted to 70% ethanol. After 4 hr at -20° the samples were centrifuged (2000 g, 10 min). The glycogen pellets were washed four times with 70%
ethanol and then assayed for radioactivity by liquid scintillation counting.

**Lipogenesis.** This was done according to the method of Moody et al. [16]. Incorporation of D-[3-3H]glucose into toluene-extractable acylglycerides was measured after incubation of 3T3 adipocytes (35 mm plate per condition) with 1 mL Krebs-Ringer-phosphate buffer (see below) in the absence or presence of sulphonylurea or insulin as indicated. Lipogenesis was initiated by the addition of 50 µL of 2 mM [3H]glucose (0.5 µCi). After incubation (90 min, 37°) the cells were dissolved by addition of 2 mL toluene-based scintillation cocktail. Following 30 min of incubation under vigorous shaking and transfer of the mixture into scintillation vials, the radioactivity was measured in the lipid phase after phase separation had been completed (usually 10–16 hr).

**Glucose transport.** This was measured by the uptake of 2-deoxyglucose.

3T3 adipocytes (according to [17, 18] with modifications): 35 mm plates were incubated (37°) with 1 mL of Krebs-Ringer-phosphate buffer (140 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl₂, 1.25 mM MgSO₄, 5 mM sodium phosphate, pH 7.4) in the absence or presence of sulphonylurea drug or insulin for the periods indicated. Uptake was initiated by the addition of 50 µL of 2 mM 2-[3H]-deoxyglucose (10 µCi/mL). After 5 min incubation in the continuous presence of sulphonylurea and/or insulin, uptake was terminated by rapid washing with an excess of ice-cold PBS containing 10 mM glucose, 0.3 mM phloretin. The monolayers were solubilized in 1 mL of 0.2% SDS. The radioactivity was measured by liquid scintillation counting. To correct for radioactivity non-specifically associated with the cells or entrapped in extracellular spaces, uptake was determined in parallel in the presence of the transport inhibitor cytochalasin B (25 µM). These values, which accounted for up to 15% of the total radioactivity of the uninhibited plates, were subtracted to obtain specific glucose transport.

**Rat diaphragm.** Intact washed rat diaphragms were incubated (30 min, 37°) in HEPES-buffered saline (25 mM HEPES, 120 mM NaCl, 5 mM KCl, 1.5 mM CaCl₂, 1 mM MgCl₂, 5 mM glucose, 0.5 mM sodium pyruvate, 1.5 mM KH₂PO₄, pH 7.4) under constant bubbling with CO₂/O₂. The diaphragms were then washed twice with the same buffer without glucose and further incubated (30 min) in 5 mL of glucose-free buffer in the presence of sulphonylurea or insulin. Glucose transport was initiated by addition of 50 µL of 10 mM 2-[3H]-deoxyglucose (10 µCi/mL) in the absence or presence of 25 µM cytochalasin B (control). After 15 min, the diaphragms were rinsed four times with ice-cold buffer containing 10 mM glucose and 25 µM cytochalasin B, blotted with filter paper and homogenized. Portions of the homogenate were used for protein determination. One millilitre portions of the supernatant (prepared as above) were mixed with 10 mL scintillation cocktail and counted for radioactivity. Specific glucose transport (dpm/mg of protein) was calculated as the difference between the diaphragm-associated radioactivity measured in the absence (total uptake) and presence of cytochalasin B (non-specific uptake).

Under these experimental conditions transport was linear for 30 min.

**Glycogen synthase.** This was assayed as described previously [19], with the following modifications. After addition of 10 µL of diaphragm homogenate (see above) to 200 µL of 25 mM Tris-HCl (pH 7.4), 200 mM NaF and 10 mM EDTA (pre-incubated at 30°), containing either 0.1 or 100 nM glucose-6-phosphate, the reaction was initiated by supplementing 0.2 mM [U-14C]UDP-glucose (10 µCi), after 15 min the reaction was terminated by the addition of 2.5 mL of ice-cold 66% ethanol and filtration over pre-wetted Whatman GF/C glass fibre discs. The filters were washed, dried and counted for radioactivity. Blanks were assayed by adding the homogenate to tubes containing the complete reaction mixture plus ice-cold ethanol. The fractional velocity as the parameter for the portion of glycogen synthase active in vivo (I-form) toward the total enzyme contents (I- + D-forms) at the time-point of homogenization was calculated as the ratio between the activities measured at 0.1 (I-form) and 10 mM glucose-6-phosphate (I- + D-forms) [20].

**GPAT.** This was assayed as described previously [21], with the following modifications. The incubation mixture contained 50 mM Tris-HCl (pH 7.4), 200 mM KCl, 1 mM DTT, 150 µM palmitoyl-CoA, 2 mg/mL BSA, 0.2 mM [3H]glycerol-3-phosphate (2 µCi) and homogenate from 3T3 adipocytes (see above) in a final volume of 0.5 mL. The reaction was started by addition of 50 µL of homogenate. After incubation (5 min, 37°) the reaction was stopped with 2 mL of water-saturated butanol, followed by 1.5 mL of butanol-saturated water. The butanol phase was separated and washed twice. An aliquot was counted for radioactivity. Under these conditions the rate of product formation was linear for at least 15 min. The radiolabelled products formed were primarily phosphatidic acid (65–70%) and lysophosphatidic acid (20–25%), as determined by TLC (not shown).

**PKA.** This was assayed according to a published method [22], with the following modifications. The reaction mixture contained 25 µL of rat adipocyte cytosol, 0.4 µM kemptide, 40 mM Tris-HCl (pH 7.2), 2 mM DTT, 12.5 mM MgCl₂, 0.1 mM PMSF, 1 mM IBMX, 100 µM [γ-32P]ATP (1 µCi) with or without 1 µM cAMP in a total volume of 100 µL. After incubation (10 min, 30°) the reaction mixture was chilled on ice, then supplemented with 3 mL of 75 mM phosphoric acid, 100 mM NaF and 10 mM ATP, and immediately spotted on phosphocellulose filters (Whatman P18). After extensive washing with 75 mM phosphoric acid, the filters were dried and counted for radioactivity. The PKA activity was expressed as the ratio between 32P-incorporation into kemptide with and without cAMP. This activity ratio is a parameter for the portion of PKA active in vivo toward total cellular PKA at the time-point of homogenization [23].

**cAMP-specific PDE.** This was assayed as described previously [24, 25], with the following modifications. Up to 50 µL of LDM from rat adipocytes were incubated (5 min, 30°) with 500 nM [2,8-3H]cAMP (100 nCi) in 50 mM Tris-HCl (pH 7.4), 0.5 mM DTT, 5 mM MgCl₂ and 50 µM PMSF in a total volume of 0.25 mL. The incubation was terminated by the
sequential addition of 30 μL of 10 mM IBMX and 120 μL of 0.1 N HCl and heating (5 min, 95°C). After neutralization [120 μL of 0.1 N KOH and 80 μL of 250 mM Tris-HCl (pH 7.4), 10 μL of crude 5'-nucleotidase (5 mg/mL) (Crotalus atrox) was added to the mixture. The reaction (30 min, 37°C) was terminated by the addition of 60 μL of 200 mM EDTA and 5 mM adenosine. Unreacted cAMP was removed by the addition of 1 mL of a 1:3 slurry of Dowex AG-1X8 (Biorad, München, Germany). Solutions were shaken (5 min, 4°C) and centrifuged (1000 g, 5 min). Radiolabelled adenosine remaining in the supernatant was determined by liquid scintillation counting. The assay was proportional up to 100 μg of protein and linear for 20 min.

**Determination of cAMP levels.** Rat adipocytes were homogenized (4°C) in the incubation medium (0.4 mL 5 × 10^5 cells/mL) with 0.6 mL of ice-cold 10% TCA. After 2 min on ice and subsequent centrifugation (12,000 g, 5 min, 0°C), the supernatant was extracted with diethyl ether and used for determination of the cAMP concentration in the organic phase by a radioimmunoassay kit (Amersham-Buchler, Braunschweig, Germany).

**Lipolysis.** This was assayed as the release of glycerol or fluorescent fatty acids from prelabelled rat adipocytes. For fluorescent labelling of adipocyte lipids, 12 mL of adipocyte suspension (2.5 × 10^6 cells/mL of Hepes-based Krebs-Ringer buffer containing 0.5 mM glucose and 0.75% BSA) was incubated (90 min, 37°C) with 0.3 nM insulin and 0.1 mM 12-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino) dodecanoic acid. Subsequently, the adipocytes were washed four times with 50 mL DMEM containing 5.5 mM glucose, 3% BSA and antibiotics by flotation (250 g, 1 min), suspended in the same medium at 5% lipocrit, incubated (15 min, 37°C) with 1 μM isoproterenol and then supplemented with sulphonylurea or insulin. After incubation (4 hr, 37°C), 1 mL aliquots were filtered (Whatman GF/C glass fibre filters). Portions of the filtrate (which quantitatively contained the released glycerol and fatty acids as well as degradation products derived thereof) were used for determination of glycerol and fluorescent fatty acids. For fatty acid determination, 500 μL of the filtrate were dried under vacuum, dissolved in 50 μL tetrahydrofuran and 5 μL aliquots were analysed by TLC [silica gel Si60, acetic acid:petrol ether:ethanol (3.5:1.5:0.5) v/v]. The total amount of fluorescent fatty acid and degradation products was calculated by fluorometric scanning of the TLC plate (total area). For glycerol determination, 200 μL of the filtrate were added to 800 μL water, heated (10 min, 70°C) and then successively made 3% (v/v) perchloric acid and 13% (v/v) carbon tetrachloride. The samples were mixed and centrifuged (12,000 g, 5 min). After neutralization with KOH the supernatant was assayed for glycerol using the spectrophotometric method of Wieland [26].

**Immunoblot analysis of GLUT4.** This was performed with polyclonal affinity-purified rabbit antibodies raised against a synthetic peptide corresponding to the COOH-terminal domain of rat GLUT4 (residues 495–509) [27]. The plasma membrane and LDM fractions were subjected to SDS-PAGE (25 μg protein/lane) and electrophoretically transferred onto nitrocellulose filters [28]. Incubations of the filters with primary and secondary antibodies ([125I]-anti-rabbit IgG from goat), autoradiography and quantitative evaluation of the immunoreactive material by densitometry were carried out as described previously [12].

**Immunoprecipitation of GLUT4.** This was performed according to published procedures [29] with the following modifications: 200 μL of homogenate (100 μg of protein) were centrifuged (150,000 g, 60 min, 4°C), the pellet was dissolved in 50 μL of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 6 M urea and 5% SDS, heated (60°, 5 min) and again centrifuged. The supernatant was supplemented with 2.5 mL of immunoprecipitation buffer [29] containing 1% TX-100 and then with 50 μL anti-GLUT4 antibody which had been adsorbed to protein A-Sepharose (50 μL of antiserum was incubated with 50 μg protein A-Sepharose beads in...
Extra-pancreatic effects of sulphonylurea drugs

8O
8o
.0 in
6 8 40
o~
20
81x577
600
300
~> 200 ~
0.1 10 100
0.01
drug
concen- lrolion (/tM)
101x540
300
~ 200 ~
500
0
400
0
300
°o ~, 200 ~
100
°o ~, 300
°o ~, 400
°o ~, 200
°o ~, 100
°o ~, 500
°o ~, 200
°o ~, 100
°o ~, 50
°o ~, 10
°o ~, 1
°o ~, 0.01
0.1 10 100
0.01
drug concentrotion (nM)
324x661
0.01 0.1 1 10 100
0.1
0
insulin concentrotion (nM)
321x577
0.01 0.1 1 10 100
0.1
0
insulin concentrotion (nM)

Fig. 2(a). 2-Deoxyglucose transport into isolated rat diaphragms was assayed after incubation with the indicated concentrations of glimepiride and glibenclamide or 300 nM insulin for 30 min or 4 hr. The diaphragm-associated 3H-radioactivity measured for the basal state (in the absence of drug or insulin) and corrected for non-specific trapping (in the presence of 25 μM cytochalasin B) was set at 100%. Each point represents the mean (± SD) of four different diaphragm preparations with four determinations each. (b)-(d) 2-Deoxyglucose transport into 3T3 adipocytes was assayed after incubation of 35 mm plates for various periods (panel b) or 20 hr (panels c and d) with 20 μM glimepiride and glibenclamide (panels b and d) or the indicated drug concentrations or 30 nM insulin (panel c) prior to further incubation in the absence (panels b and c) or presence of various concentrations of insulin (panel d) for 15 min. The cell-associated 3H-radioactivity measured for the basal state (in the absence of drug or insulin) and corrected for non-specific trapping (in the presence of 25 μM cytochalasin B) was set at 100%. Each point represents the mean (± SD) of five different cell preparations with four determinations each.

RESULTS

Stimulation of glucose utilization (lipogenesis and glycogenesis)

Long-term incubation of 3T3 adipocytes with glimepiride and glibenclamide concentration-dependently stimulated lipogenesis up to 4-fold (corresponding to 35–40% of the maximal insulin-induced lipogenesis as observed with 30 nM insulin after 15 min incubation) (Fig. 1a). This effect was clearly more pronounced after 20 hr compared to 4 hr incubation. The ED₅₀-values for glimepiride and glibenclamide were comparable (1.7 vs 2.9 μM) and independent of the incubation time.

Incubation for 4 hr of isolated rat hemidiaphragms with glimepiride and glibenclamide concentration-dependently stimulated glycogenesis up to 2.5-fold (corresponding to 65% of the maximal insulin effect as observed with 100 nM insulin after 30 min incubation) (Fig. 1b), with ED₅₀-values of 0.4 μM (glimepiride) and 0.8 μM (glibenclamide). Thus, the overall glucose-utilizing pathways of lipid and glycogen synthesis are stimulated by both drugs, with glimepiride being slightly more effective than glibenclamide.

Stimulation of glucose transport

Under physiological plasma glucose levels glucose transport is thought to be rate-limiting for lipogenesis and glycogenesis [33]. Therefore, it was wondered whether glimepiride and glibenclamide stimulated transport of the non-metabolizable sugar analogue, 2-deoxyglucose, in 3T3 adipocytes and isolated rat diaphragms. Incubation of the diaphragms for 30 min
Fig. 3(a) and (b). Total amount of GLUT4 protein in 3T3 adipocytes was assayed after incubation of 150 mm plates with the indicated concentrations of glimepiride and glibenclamide (panel a) or 20 µM drug (panel b) for 20 hr (panel a) or the indicated periods (panel b). The immunoreactive GLUT4 in total cellular membranes measured for the basal state (in the absence of drug or insulin) was set at 100%. Each value represents the mean (+SD) of three different cell preparations with two determinations each.

Fig. 3(c). The amount of newly synthesized insulin was set at 100%. Each point represents the mean (+SD) of three cell preparations with four determinations each.

with glimepiride and glibenclamide concentration-dependently increased glucose transport up to 1.7-fold with ED₅₀-values of 3.2 µM for both drugs (Fig. 2a). Drug exposure for 4 hr caused a left-ward shift of the dose–response curves (ED₅₀-value = 0.7 µM for glimepiride, 1.2 µM for glibenclamide) with no increase in the maximal response. In contrast, maximal glimepiride and glibenclamide stimulation of 2-deoxyglucose transport in 3T3 adipocytes required 24 hr drug exposure (Fig. 2b). Under these conditions glimepiride and glibenclamide concentration-dependently stimulated glucose transport up to 7- and 6-fold with ED₅₀-values of 3.2 and 5.2 µM, respectively (corresponding to 25–30% of the maximal insulin stimulation) (Fig. 2c).

Submaximal insulin concentrations (0.05–1 nM) plus glimepiride or glibenclamide (20 µM) stimulated 2-deoxyglucose transport in an additive fashion, which, however, did not exceed the maximal insulin effect (Fig. 2d). The ED₅₀-value for glucose transport stimulation by insulin (1.2 nM) was reduced in the presence of glimepiride (0.5 nM) and glibenclamide (0.8 nM). Thus, in 3T3 adipocytes, both sulphonylureas directly activated glucose transport independently of insulin, and potentiated insulin-stimulated glucose transport, albeit to a moderate degree. Stimulation of glucose transport may be based on increased de novo synthesis of GLUT protein and/or recruitment of GLUT from intracellular stores (LDM) to the cell surface (termed as translocation [34, 35]). To study these possibilities, the amount of GLUT4, the major insulin-regulatable GLUT isoform in 3T3 adipocytes (for a review see Ref. [36]), was determined in total cellular membranes or, after subcellular fractionation, in the LDM and plasma membranes by immunoblotting with anti-GLUT4 antibodies. Incubation (20 hr) of 3T3 adipocytes with glimepiride and glibenclamide concentration-dependently increased the total amount of GLUT4 up to 2-fold (with 20 µM drug) (Fig. 3a). Long-term incubation (>4 hr) was required for a significant drug-induced increase, suggesting stimulation of GLUT4 synthesis (Fig. 3b). This was confirmed by immunoprecipitation with anti-GLUT4 antibodies of total membrane proteins from 3T3 adipocytes which had been metabolically labelled with [³⁵S]methionine for 20 hr in the presence of glimepiride or glibenclamide (Fig. 3c). Glimepiride and glibenclamide concentration-dependently increased the amount of total immunoprecipitated radiolabelled GLUT4 1.7- and 1.6-fold (at 50 µM), respectively, with ED₅₀-values (1.2 vs 2.3 µM) comparable to those observed for total immunoreactive GLUT4 (0.8 vs 1.5 µM).

In addition, both drugs stimulated translocation of GLUT4 as revealed by immunoblotting of LDM and plasma membranes with anti-GLUT4 antibodies (Table 1). Incubation (20 hr) with glimepiride and glibenclamide caused a concentration-dependent translocation of GLUT4 approaching 40–50% of the maximal insulin response, corresponding to a 3.5-fold increase of plasma membrane GLUT4.

Stimulation of glucose metabolizing enzymes.

In addition to drug-stimulated glucose transport and metabolism, the latter, at least in part, being due to increased substrate availability, glucose metabolizing enzymes may be activated in response to glimepiride and glibenclamide independently of the mass effect. Therefore, the key regulatory enzymes of lipogenesis and glycogenesis, GPAT and glycogen synthase, were investigated.

The esterification of glycerol-3-phosphate to
Table 1. Effects of sulphonylureas on the translocation of GLUT4 in 3T3 adipocytes

<table>
<thead>
<tr>
<th>Incubation</th>
<th>Total immunoreactive GLUT4 in the plasma membrane (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>8.3 ± 2.7</td>
</tr>
<tr>
<td>Insulin</td>
<td>44.2 ± 9.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sulphonylurea (μM)</th>
<th>Glimepiride</th>
<th>Glibenclamide</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>8.1 ± 3.5</td>
<td>6.8 ± 2.7</td>
</tr>
<tr>
<td>1</td>
<td>10.8 ± 2.6</td>
<td>9.6 ± 4.0</td>
</tr>
<tr>
<td>5</td>
<td>12.9 ± 3.9</td>
<td>15.9 ± 4.6</td>
</tr>
<tr>
<td>10</td>
<td>16.7 ± 4.4</td>
<td>20.3 ± 4.9</td>
</tr>
<tr>
<td>20</td>
<td>19.8 ± 5.3</td>
<td>23.6 ± 4.1</td>
</tr>
<tr>
<td>50</td>
<td>22.2 ± 4.8</td>
<td>23.1 ± 5.2</td>
</tr>
</tbody>
</table>

Translocation of GLUT4 in 3T3 adipocytes was assayed after incubation of 150 mm plates with the indicated concentrations of glimepiride and glibenclamide for 20 hr or insulin (5 nM) for 30 min.

The amount of immunoreactive GLUT4 identified by immunoblotting in the plasma membranes was calculated as the percentage of the total amount of GLUT4 recovered in cellular membranes after incubation with drug or insulin which was set at 100% for each concentration. Each value represents the mean (± SD) of four adipocyte preparations and fractionations with three determinations each.

Neutral lipids, phospholipids and (lyso)phosphatidic acid by GPAT was stimulated up to 2-fold with ED50-values of 1.9 and 3.7 μM, respectively, when assayed with homogenate from glimepiride- and glibenclamide-treated 3T3 adipocytes (Fig. 4). The concentration-dependent stimulation was more pronounced after 20 hr than 4 hr incubation. After 4 hr exposure of isolated rat diaphragms to glimepiride and glibenclamide the fractional velocity for glycogen synthase concentration-dependently increased up to 6-fold (at 20 μM) (Fig. 5a). Glimepiride was more effective than glibenclamide (ED50-value 0.8 vs 2.0 μM). Gel filtration over Sephadex G-25 of homogenates prepared from drug-treated diaphragms did not inhibit the activation of glycogen synthase (data not shown), suggesting that the activation was not due to elevated levels of glucose-6-phosphate as a consequence of increased glucose transport. Total glycogen synthase activity (L- and D-forms) as measured in the presence of 10 mM glucose-6-phosphate was not altered. Both drugs (at 10 μM) and low concentrations of insulin (up to 10 nM) stimulated the fractional velocity in an additive fashion (data not shown), approaching 120% of the maximal insulin effect. The ED50-value for insulin stimulation (35 nM) was reduced in the presence of glimepiride (16 nM) or glibenclamide (23 nM). Elevated basal and insulin-stimulated fractional velocities were not observed if the homogenate was prepared 15 min after drug addition. Effects on the cAMP regulatory cascade

GPAT and glycogen synthase, which are both stimulated by glimepiride and glibenclamide in 3T3 adipocytes and the rat diaphragm, are regulated...
Table 2. Effects of sulphonylureas on the isoproterenol-stimulated lipolysis in rat adipocytes

<table>
<thead>
<tr>
<th>Incubation</th>
<th>Total glycerol release (%)</th>
<th>Fluorescent fatty acid release (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>30.6 ± 8.9</td>
<td></td>
</tr>
<tr>
<td>Sulphonylurea (μM)</td>
<td>Glimepiride</td>
<td>Glibenclamide</td>
</tr>
<tr>
<td>0.5</td>
<td>92.8 ± 15.8</td>
<td>95.2 ± 12.4</td>
</tr>
<tr>
<td>1</td>
<td>76.4 ± 18.9</td>
<td>82.0 ± 19.3</td>
</tr>
<tr>
<td>2</td>
<td>70.8 ± 14.5</td>
<td>68.4 ± 12.5</td>
</tr>
<tr>
<td>5</td>
<td>63.6 ± 11.6</td>
<td>58.7 ± 10.4</td>
</tr>
<tr>
<td>10</td>
<td>60.1 ± 14.2</td>
<td>48.8 ± 16.7</td>
</tr>
<tr>
<td>20</td>
<td>56.5 ± 8.9</td>
<td>44.8 ± 12.0</td>
</tr>
<tr>
<td>50</td>
<td>53.1 ± 12.7</td>
<td>42.7 ± 9.7</td>
</tr>
<tr>
<td>Insulin</td>
<td>36.7 ± 10.3</td>
<td></td>
</tr>
<tr>
<td>Sulphonylurea (μM)</td>
<td>Glimepiride</td>
<td>Glibenclamide</td>
</tr>
<tr>
<td>0.5</td>
<td>91.7 ± 24.9</td>
<td>95.7 ± 17.8</td>
</tr>
<tr>
<td>1</td>
<td>76.3 ± 19.4</td>
<td>86.4 ± 28.1</td>
</tr>
<tr>
<td>2</td>
<td>72.3 ± 14.1</td>
<td>73.7 ± 18.5</td>
</tr>
<tr>
<td>5</td>
<td>67.3 ± 20.5</td>
<td>69.6 ± 16.4</td>
</tr>
<tr>
<td>10</td>
<td>63.1 ± 13.1</td>
<td>64.7 ± 18.6</td>
</tr>
<tr>
<td>20</td>
<td>58.3 ± 19.4</td>
<td>59.7 ± 12.1</td>
</tr>
<tr>
<td>50</td>
<td>56.3 ± 10.5</td>
<td>55.3 ± 13.6</td>
</tr>
</tbody>
</table>

The PKA activity ratio is assumed to reflect mainly the intracellular cAMP concentration at the time-point of homogenization [23]. Consequently, it was studied whether glimepiride and glibenclamide caused a reduction in the high cytosolic cAMP level in isoproterenol-stimulated adipocytes. Care was taken to minimize degradation of cytosolic cAMP after homogenization of the isoproterenol- and, subsequently, drug-treated cells (see Materials and Methods). Both drugs provoked a concentration-dependent decline of cAMP levels up to 50% of the isoproterenol-induced concentration (Table 3). Finally, it was studied whether sulphonylureas reduced cytosolic cAMP by promoting its degradation. In fact, the activity of the particulate low K_m cAMP-specific PDE in LDM from rat adipocytes which had been incubated with glimepiride and glibenclamide for 2 hr concentration-dependently increased up to 2-fold (at 20 μM) compared to untreated control cells (Fig. 7), with ED_{50}-values of 0.9 and 2.0 μM, respectively.

**DISCUSSION**

A large number of studies during the past three decades have demonstrated multiple effects of sulphonylurea drugs on isolated normal and insulin-resistant rat [12, 37-43] and mouse 3T3 adipocytes [44-46], cultured myocytes [47-51], isolated rat diaphragms [52] and perfused rat hind limbs [53] (for a review see Ref. [54]). Among them are the stimulation of glucose transport [12, 37, 38, 41, 44-46], lipogenesis [40] and glycogenesis [43], as well as the inhibition of lipolysis [39]. The multiple effects of sulphonylureas on glucose utilization in vitro suggest the induction of one or several basic molecular mechanism(s) which is(are) responsible for the regulation of key metabolic pathways.

As described in this study, the maximal 7-fold stimulated glucose transport in 3T3 adipocytes after 20 hr incubation with glimepiride and glibenclamide is explained in part by the 4-fold amount of plasma membrane GLUT4. This may be based on both activated synthesis and translocation of GLUT4. Stimulation of GLUT gene expression and translocation by tolbutamide and glibenclamide has been described previously for adipose [41, 42, 44] and muscle cells [48, 50]. Since glimepiride and insulin stimulations are additive only, glimepiride may regulate GLUT4 translocation by bypassing the insulin signal transduction cascade. Elevated levels of phosphorylated GLUT4 in isolated rat adipocytes incubated with glucose, insulin and glutamine in primary culture [12], or in rat adipocytes isolated from Streptozotocin-diabetic rats [55], have been correlated with diminished glucose transport activity [56]. There is some evidence for Ser/Thr-phosphorylation of GLUT4 by PKA during induction of insulin resistance [57-59]. Treatment of insulin-resistant cultured adipocytes with glimepiride reduces the GLUT4 phosphorylation state to a significantly higher degree than insulin [12], possibly by interference with PKA activity. This would explain the drug’s ability to induce GLUT4 translocation in insulin-resistant adipocytes if only the dephos-
Extra-pancreatic effects of sulphonylurea drugs

Table 3. Effects of sulphonylureas on the cAMP-level in rat adipocytes

<table>
<thead>
<tr>
<th>Incubation</th>
<th>cAMP [pmol/10^6 adipocytes]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>26.3 ± 6.5</td>
</tr>
<tr>
<td>Isoproterenol</td>
<td>175.6 ± 23.7</td>
</tr>
<tr>
<td>Isoproterenol + insulin</td>
<td>52.5 ± 13.6</td>
</tr>
<tr>
<td>Isoproterenol + sulphonylurea (μM)</td>
<td>Glimepiride</td>
</tr>
<tr>
<td>0.5</td>
<td>168.7 ± 44.3</td>
</tr>
<tr>
<td>1</td>
<td>161.0 ± 29.6</td>
</tr>
<tr>
<td>2</td>
<td>148.8 ± 21.3</td>
</tr>
<tr>
<td>5</td>
<td>127.8 ± 23.4</td>
</tr>
<tr>
<td>10</td>
<td>113.8 ± 27.6</td>
</tr>
<tr>
<td>20</td>
<td>103.3 ± 31.6</td>
</tr>
<tr>
<td>50</td>
<td>110.4 ± 20.5</td>
</tr>
<tr>
<td>100</td>
<td>122.5 ± 23.1</td>
</tr>
</tbody>
</table>

CAMP levels in the cytosol of isolated rat adipocytes were assayed after incubation of 20 mL of adipocyte suspension (5 × 10^5 cells/mL) in the absence (basal) or presence of 1 μM isoproterenol for 15 min and subsequently with the indicated concentrations of glimepiride and glibenclamide or 5 nM insulin for 4 hr. Each value represents the mean (± SD) of four different adipocyte preparations with four determinations each.

![Graph](Image)

Fig. 7. cAMP-specific PDE activity in LDM from isolated rat adipocytes was assayed after 2 hr incubation of 40 mL of adipocyte suspension (5 × 10^5 cells/mL) with the indicated drug concentrations or 5 nM insulin. Each point represents the mean (± SD) of five different adipocyte preparations with two determinations each.

GPCR phosphorylated GLUT4 is competent for translocation and residence at the plasma membrane. Glimepiride and glibenclamide lead to activation of GPAT and glycogen synthase presumably through impairment of cAMP-dependent phosphorylation of the enzymes. This is also the mechanism for their stimulation by insulin [60, 61], and would parallel the postulated molecular mechanism for the glimepiride stimulation of GLUT4 translocation. In support of this hypothesis is the fact that glimepiride and glibenclamide reduce the portion of active PKA within the same concentration range effective in stimulating glucose transport. A moderate inhibition of PKA has been described previously for tolbutamide [62]. The diminished PKA activity is due mainly to significantly lowered levels of cytosolic cAMP after glimepiride- and glibenclamide-treatment of rat adipocytes. However, a direct inhibition of the catalytic subunit of PKA, cannot be excluded, as it has been demonstrated for PKA from rat liver [63, 64]. In parallel with reduced cytosolic cAMP levels, the drugs stimulate the activity of the microsomal low K_m cAMP-specific PDE in rat adipocytes within the same concentration range. This corroborates previous reports concerning sulphonylurea action on PDE activity [65, 66]. At present it is not known whether a sulphonylurea-induced inhibition of adenylate cyclase, as reported for rat heart and liver [67], supports the decline of cAMP levels. The inhibitory effects of glimepiride and glibenclamide on cAMP level and PKA activity are confirmed by the antagonism of isoproterenol-stimulated lipolysis in drug-treated rat adipocytes. Significantly less pronounced antilipolytic activity has been demonstrated for tolbutamide [39].

That treatment of 3T3 adipocytes with glimepiride stimulates a glycosyl-phosphatidylinositol-specific phospholipase C [10] may be of relevance for a unifying molecular basis for the inhibition of PKA and stimulation of PDE by sulfonylureas. The degradation products of glycosyl-phosphatidylinositol lipids and/or glycosyl-phosphatidylinositol-anchored membrane proteins, phosphoinositolglycans and phosphoinositolglycan-peptides, have been documented to inhibit PKA [68, 69] and to stimulate PDE [70, 71] if assayed in cell-free systems derived from adipocytes or hepatocytes which have been pre-incubated with these structures.

The physiological meaning of the stimulation of glucose utilization and inhibition of lipolysis by sulphonylureas observed in vitro is still a matter of intense debate (for two opposing views see Refs. [54, 72]). The ED_{50} values of glimepiride and glibenclamide in these in vitro assays were two to three orders of magnitude higher than the concentration of free not protein-bound drug, as usually measured in the serum of NIDDM patients (1–10 nM). However, local accumulation of sulphonylureas in muscle and fat tissues cannot be excluded. Extra-pancreatic effects have been thought to be responsible for the hypoglycemic action of sulphonylureas following the acute phase of insulin
release [73–75; for a review see Ref. 76]. In rabbits and dogs the blood sugar lowering phase after the initial period of insulin release is significantly longer than for glimepiride than for glibenclamide [9]. To support extra-pancreatic effects this difference should be reflected in the effects of the two drugs on glucose utilization and its underlying regulatory mechanisms in vitro. The present study reveals that, at this level, glimepiride and glibenclamide exhibit similar effective concentration ranges and maximal responses. However, the data obtained from many assays of glimepiride and glibenclamide resulted in slightly lower calculated ED_{50} and IC_{50} values, respectively. This is reflected in subtle left-ward shifts of the dose–response curves for glimepiride. The differences obtained with these experimental designs were only at the threshold of significance. Nevertheless, they were obtained with a considerable number of independent assays carried out with different cell types. Taken together, the present study strengthens the view that: (1) the multiple effects of sulfonylureas on fat and muscle cells in vitro are based on a common molecular mechanism, i.e., the inhibition of cAMP-dependent phosphorylation, which is used by glimepiride more efficiently than by glibenclamide; (2) the prolonged hypoglycemic action of sulfonylureas in the absence of correspondingly elevated plasma insulin levels in vivo, which is more pronounced with glimepiride than glibenclamide, is correlated with their efficacy in stimulating glucose utilization and the underlying regulatory steps in muscle and fat tissues.

Acknowledgements—We thank S. Grey for technical assistance during some experiments, Drs A. Dudenhofer and E. Draeger for valuable discussions throughout the course of the study, Dr P. Schindler for suggesting the use of fluorescent fatty acids for the lipolysis assay and M. Forster (all Hochstein AG Frankfurt) for critical reading of the manuscript.

REFERENCES


